Sabirnetug trial failure forces Acumen Pharmaceuticals to reassess Alzheimer’s drug development strategy
Acumen Pharmaceuticals halts sabirnetug after its Phase 2 Alzheimer's trial fails despite amyloid reduction. Discover what the findings mean.
Features & Analysis
Pharma & Biotech
JCR’s enzyme therapy reaches Kuwait. Can crossing the blood-brain barrier change Hunter syndrome care?
JCR Pharmaceuticals has received conditional marketing authorization for IZCARGO in Kuwait, its second market outside Japan. The blood-brain barrier-penetrating enzyme therapy is designed to address both systemic and neurological features of Hunter syndrome, although its global Phase 3 programme remains ongoing.
Pharma & Biotech
Is JCR unlocking the CNS for lysosomal storage diseases before gene therapy gets there?
Find out how JCR Pharmaceuticals is redefining lysosomal disease therapy with brain-targeted delivery platforms.
Pharma & Biotech
Is givinostat’s entry into Japan a turning point for DMD care and for JCR Pharmaceuticals’ rare disease strategy?
Find out how Italfarmaco and JCR are bringing the DMD drug givinostat to Japan and what it means for rare disease innovation in Asia.